Bruce Evan Johnson

Bruce Evan Johnson's AcademicInfluence.com Rankings

Bruce Evan Johnson

Philosophy

#6719

World Rank

#9807

Historical Rank

Logic

#3841

World Rank

#5061

Historical Rank

philosophy Degrees

Bruce Evan Johnson

Biology

#9112

World Rank

#12277

Historical Rank

Genetics

#926

World Rank

#1022

Historical Rank

Molecular Biology

#1216

World Rank

#1242

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Bruce Evan Johnson's Degrees

Doctorate Medicine Stanford University

Why Is Bruce Evan Johnson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bruce Evan Johnson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (2004) (9387)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (2005) (3818)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007) (3564)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
Somatic mutations affect key pathways in lung adenocarcinoma (2008) (2640)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing (2012) (1620)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005) (1538)
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses (2001) (1518)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. (2005) (1488)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. (2014) (1364)
Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016) (1064)
LKB1 modulates lung cancer differentiation and metastasis (2007) (975)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. (2008) (845)
The BATTLE trial: personalizing therapy for lung cancer. (2011) (810)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. (2016) (768)
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (734)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population (2009) (646)
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development (2005) (632)
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. (2016) (575)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib (2006) (549)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. (2005) (527)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. (2011) (474)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. (2006) (461)
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. (2003) (449)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry (2010) (443)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. (2006) (440)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. (2010) (418)
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. (2005) (402)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials (2009) (386)
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 (2004) (353)
Small-cell lung cancer (2005) (330)
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. (2008) (317)
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2015) (312)
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. (2007) (309)
Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays (2000) (307)
Institutional implementation of clinical tumor profiling on an unselected cancer population. (2016) (303)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer (2013) (299)
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience (2015) (297)
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. (2002) (297)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance (2009) (297)
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. (2007) (283)
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
Small cell lung cancer. (2008) (248)
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 (2000) (248)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. (2006) (246)
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors (2019) (242)
T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. (1985) (240)
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions (2013) (239)
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. (2002) (232)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. (2005) (231)
Five‐Year Survival in EGFR‐Mutant Metastatic Lung Adenocarcinoma Treated with EGFR‐TKIs (2016) (231)
A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening (2006) (221)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. (2008) (216)
Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States (2011) (213)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. (2018) (209)
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib (2010) (202)
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. (2004) (195)
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. (2010) (191)
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. (2007) (184)
A single-cell landscape of high-grade serous ovarian cancer (2020) (184)
Phase II study of imatinib in patients with small cell lung cancer. (2003) (183)
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. (2007) (176)
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations (2012) (171)
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity (2005) (165)
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. (2013) (164)
Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America (2002) (161)
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer (2009) (159)
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. (2005) (158)
Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems (2020) (144)
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations (2005) (142)
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. (2005) (136)
Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (2006) (134)
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) (2017) (134)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. (2002) (134)
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. (2010) (132)
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. (2014) (132)
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. (2013) (128)
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers (2008) (127)
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma (2020) (127)
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (126)
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). (2019) (125)
High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines (2004) (125)
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. (2009) (123)
Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience (2019) (119)
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (2010) (116)
Spatially organized multicellular immune hubs in human colorectal cancer (2021) (109)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma (2008) (107)
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium (2017) (107)
Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma (2009) (106)
State of the art: Response assessment in lung cancer in the era of genomic medicine. (2014) (106)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
The impact of genomic changes on treatment of lung cancer. (2013) (102)
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium (2015) (101)
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer (2007) (100)
Molecular mapping of deletion sites in the short arm of chromosome 3 in human lung cancer (1990) (100)
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer (2012) (99)
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. (2008) (98)
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial (2016) (96)
Management of small cell lung cancer. (1999) (96)
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer (2021) (95)
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. (2004) (92)
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer (2009) (86)
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. (2011) (86)
Integration of Molecular Profiling into the Lung Cancer Clinic (2009) (85)
Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients (2006) (84)
Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. (2019) (82)
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. (2014) (82)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer (2015) (82)
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. (2012) (78)
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. (2013) (77)
Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics (2012) (76)
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer (2007) (73)
MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. (2019) (71)
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. (2009) (70)
Inhibition of the Met Receptor in Mesothelioma (2005) (69)
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium (2016) (68)
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer (2016) (68)
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). (2013) (68)
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer (2018) (66)
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) (66)
Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma (2008) (61)
Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples (2000) (60)
Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? (2005) (59)
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer (2019) (56)
Patient‐reported receipt of and interest in smoking‐cessation interventions after a diagnosis of cancer (2011) (55)
Advances in Brief Gefitinib Induces Apoptosis in the EGFRL 858 R Non – Small-Cell Lung Cancer Cell Line H 3255 (2004) (55)
Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer (2011) (53)
Chemotherapy for a Patient with Advanced Non-Small-Cell Lung Cancer during Pregnancy: A Case Report and a Review of Chemotherapy Treatment during Pregnancy (2001) (52)
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab (2012) (52)
Farnesyl Transferase Inhibitors for Patients with Lung Cancer (2004) (51)
Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer (2007) (51)
Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery (2009) (50)
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). (2018) (50)
Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. (2012) (50)
Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. (2014) (49)
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). (2015) (49)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer (2006) (46)
Paraneoplastic syndromes associated with small cell lung cancer. (2006) (46)
Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC (2005) (46)
Paraneoplastic syndromes in lung cancer (1992) (45)
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. (2015) (45)
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2019) (45)
Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer (2015) (45)
Realizing the potential of plasma genotyping in an age of genotype-directed therapies. (2014) (44)
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung (2013) (43)
Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI (2013) (43)
Basic treatment considerations using chemotherapy for patients with small cell lung cancer. (2004) (42)
Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. (2012) (42)
Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. (2005) (42)
Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy (2013) (41)
Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer (2021) (41)
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC (2005) (40)
Adjuvant chemotherapy for surgically resected non-small cell lung cancer. (2012) (39)
Chapter 9: The MGH‐HMS Lung Cancer Policy Model: Tobacco Control Versus Screening (2012) (39)
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. (2013) (39)
A Metabolic Study of Patients with Lung Cancer and Hyponatremia of Malignancy (2006) (38)
Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. (2012) (37)
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (2012) (37)
Imaging of lung cancer in the era of molecular medicine. (2011) (36)
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer (2005) (34)
Involvement of the RAFI locus, at band 3p25, in the 3p deletion of small‐cell lung cancer (1991) (33)
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma (2018) (32)
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. (2016) (32)
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results (2008) (31)
Adopting helical CT screening for lung cancer (2008) (30)
Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas (2000) (30)
Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis. (2021) (30)
Parity and risk of lung cancer in women. (2006) (30)
Human Small Cell Lung Cancer Cells Produce Brain Natriuretic Peptide (1999) (30)
Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. (2018) (30)
Imatinib in small cell lung cancer. (2003) (30)
Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With Lung Cancer (2021) (28)
TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract (1995) (27)
LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). (2017) (26)
The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute (2020) (25)
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial (2005) (25)
Lipid effects of celiprolol, a new cardioselective β‐blocker, versus propranolol (1989) (24)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors (2007) (24)
Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin (1993) (24)
Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines (1998) (24)
Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma (2004) (23)
An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). (2016) (23)
Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474 (2005) (22)
Small cell lung cancer clinical practice guidelines in oncology. (2006) (22)
Genomic Characterization of de novo Metastatic Breast Cancer (2020) (21)
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. (2021) (21)
Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma (2005) (20)
403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer (2020) (20)
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (2022) (20)
Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome (2019) (19)
Sensitivity of Non-Small-Cell Lung Cancer Cell Lines Established from Patients Treated with Prolonged Infusions of Paclitaxel (2003) (19)
Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. (2016) (19)
Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer (2009) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). (2020) (18)
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). (2020) (18)
8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer ( (2009) (18)
Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database. (2017) (18)
Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma (2005) (18)
Comparative effectiveness of three platinum‐doublet chemotherapy regimens in elderly patients with advanced non–small cell lung cancer (2013) (17)
Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. (2020) (17)
A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. (2003) (17)
Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). (2010) (16)
Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. (2003) (16)
Patient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non–Small Cell Lung Cancer (2005) (16)
Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. (2006) (15)
Genetic Changes in Contralateral Bronchioloalveolar Carcinomas of the Lung (2000) (15)
Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) (2014) (15)
P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study (2005) (15)
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. (2016) (15)
Expression of bcl‐2 protein is associated with shorter survival in nonsmall cell lung carcinoma (2003) (14)
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. (2003) (14)
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. (2019) (14)
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC (2008) (13)
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. (2012) (13)
Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib (2008) (13)
Divide and Conquer to Treat Lung Cancer. (2016) (13)
in squamous cell lung cancer (2011) (13)
Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. (2017) (12)
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib (2015) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3) (2018) (12)
The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. (2005) (12)
O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program (2003) (12)
O-238 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years (2003) (11)
Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women. (2011) (11)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. (2010) (10)
ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. (2012) (9)
9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC) (2011) (9)
Success of genomic profiling of non–small cell lung cancer biopsies obtained by trans‐thoracic percutaneous needle biopsy (2018) (9)
The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC). (2019) (9)
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study (2022) (8)
Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. (2018) (8)
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3 (2019) (8)
Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC) (2007) (8)
Small-cell lung cancer. (2005) (8)
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists (2021) (8)
Imatinib for Small Cell Lung Cancer, Aiming for a Target in Vivo (2004) (7)
Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors (2020) (7)
Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma (2007) (7)
Impact of EGFR mutations on treatment of non-small cell lung cancer (2006) (7)
BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. (2018) (7)
Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy (2005) (6)
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing (2020) (6)
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib (2020) (6)
O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma (2005) (6)
Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients withRASmutant solid tumors (2017) (6)
The tumor microenvironment drives transcriptional phenotypes and their plasticity in metastatic pancreatic cancer (2020) (6)
Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) (2017) (6)
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-Small Cell Lung Cancer. (2020) (6)
Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasion (2020) (6)
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing (2021) (5)
Differential Effects ofVascular Endothelial Growth Factor Receptor-2 Inhibitor ZD 6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells : Implications for Use as a SurrogateMarker of Antiangiogenic Activity (2005) (5)
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. (2008) (5)
960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC (2021) (5)
2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets (2015) (5)
P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma. (2007) (5)
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. (2019) (5)
MatchMiner: an open-source platform for cancer precision medicine (2022) (5)
A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC). (2012) (5)
The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer (2020) (5)
P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial (2019) (4)
Small cell lund cancer (1997) (4)
A phase II clinical and pharmacokinetic study of weekly paclitaxel in elderly patients with non-small cell lung cancer (2000) (4)
The survival of patients treated for limited stage small cell lung cancer has increased during the past 20 years (2000) (4)
CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC) (2019) (4)
Genomic landscape of de novo stage IV breast cancer. (2019) (3)
Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib (2020) (3)
Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC). (2013) (3)
From clinical specimens to human cancer preclinical models—a journey the NCI‐cell line database—25 years later (2019) (3)
O-306 Novel somatic mutations in the juxtamembrane domain of c-Met in small cell lung cancer: implications in cytoskeletal functions and cell motility (2003) (3)
M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome (2019) (3)
Chemotherapy and irradiation for locally advanced and metastatic pulmonary carcinoid tumors (2015) (3)
The Role of Race in Oncogenic Driver Prevalence and Outcomes in Lung Adenocarcinoma : Results from the Lung Cancer Mutation Consortium ( LCMC ) (3)
A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC). (2017) (3)
Biology and Molecular Genetics of Lung Cancer (1996) (3)
A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. (2015) (3)
MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC (2018) (3)
In-vitro effects of pemetrexed on bronchioloalveolar and adenocarcinoma of the lung (2005) (3)
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. (2021) (3)
Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience. (2014) (2)
Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer (2002) (2)
Surgical Results of the Lung Cancer Mutation Consortium 3 (LCMC 3) Trial: (2022) (2)
Phase I trial of dihydrolenperone in lung cancer patients: A novel compound within vitro activity against lung cancer (1993) (2)
Multicellular immune hubs and their organization in MMRd and MMRp colorectal cancer (2021) (2)
Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1stline therapy in patients (pts) with advanced or metastatic NSCLC (2020) (2)
A phase I study of E7070, a chloroindolyl-sulfonamide, in combination with irinotecan in gastrointestinal and thoracic carcinomas (2005) (2)
Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. (2003) (2)
Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (2014) (2)
Postdiagnosis BMI Change Is Associated with Non–Small Cell Lung Cancer Survival (2021) (2)
Emerging gene mutation targets in lung cancer. (2015) (2)
Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. (2013) (2)
Genomic profiling of non-small cell lung cancer (NSCLC) for personalized targeted therapy using CT-guided transthoracic needle biopsy (TTNB). (2012) (2)
O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma (2005) (2)
Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study. (2015) (2)
9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2009) (2)
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration. (2014) (2)
PD-156 The Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard Medical School Partners HealthCare Center for genetics and genomics experience with clinical testing for somatic EGFR mutations in NSCLC patients (2005) (2)
18 The use of a statistical model to help predict the outcome of phase III trials of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) (1997) (2)
BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation. (2018) (2)
266 POSTER Preclinical evaluation of IL-21 combination therapy with sorafenib and sunitinib in renal cell carcinoma (2006) (2)
Abstract A177: Cetuximab resistance associated with dimerization‐independence of oncogenic EGFR mutants (2009) (1)
PD-142 ErbB-3 mediates PI3K activity in gefitinib-sensitive non-smallcell lung cancer cell lines (2005) (1)
C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. (2007) (1)
PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program (2007) (1)
Novel Agents in theTreatment of Lung Cancer : Advances in EGFR-Targeted Agents (2006) (1)
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort (2022) (1)
Tumor Ablation for Patients with Lung Cancer: The Thoracic Oncologist’s Perspective (2005) (1)
myc Family DNA amplification in small cell lung cancer cell lines and tumors (1988) (1)
Toxicity and supportive care in small cell lung cancer: a consensus report (1989) (1)
Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial. (2019) (1)
Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC) (2020) (1)
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC) (2013) (1)
Phase III trials in patients with advanced stage non-small cell lung cancer: The experience in North America from 1973–1994 (2000) (1)
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer (2022) (1)
Interstitial lung abnormalities in treatment-naive advanced NSCLC patients (pts): Prevalence and impact on survival. (2014) (1)
Small Cell Lung Cancer Cell Line Derived from a Primary Tumor with a Characteristic Deletion of 3p1 (2006) (1)
A method for determining the responsiveness of a tumor to treatments with the epidermal growth factor receptor as a target (2005) (1)
P3-093: Correlative analyses of plasma cytokine / angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of 1st-line vandetanib (VAN) and / or carboplatin plus paclitaxel (CP) for advanced non small cell lung cancer (NSCLC). (2007) (1)
ARapid and Sensitive EnzymaticMethod for Epidermal Growth Factor ReceptorMutation Screening (2006) (1)
Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
Gefitinib resistance caused by a secondary mutation of the epidermal growth factor receptor (2005) (1)
Molecular markers predictive of response to EGFR inhibitors (2008) (1)
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial (2009) (1)
Abstracts Presented at the 7th Annual Meeting of the North American NeuroEndocrine Tumor Society, October 10–11, 2014, Nashville, Tennessee (2015) (1)
Lung Cancer Cells Signal Transduction through CXCR 4 and c-Kit in Small Cell Regulation of Cellular Proliferation , Cytoskeletal Function , and Updated Version (2002) (1)
Oncogenes in clinical cancer — A panel discussion (1987) (1)
State legislative trends related to biomarker testing (2022) (1)
Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists. (2021) (1)
PD-145 Long-term survival of NSCLC patients with EGFR mutationstreated with EGFR TKIs gefitinib or erlotinib (2005) (1)
53. Genomic characterization of brain metastases identifies drivers of metastatic lung adenocarcinoma (2020) (1)
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program (2021) (1)
Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. (2018) (1)
The role of and significance of autocrine growth factors and neuroendocrine markers in the development of small cell lung cancer (1997) (1)
Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI's vs. chemotherapy (2008) (1)
Development and validation of a novel EHR-based tumor progression outcome to support biomarker discovery. (2020) (1)
178 Paclitaxel by 96-hour continuous infusion in combination with cisplatin: Preliminary results of a phase II trial in patients with advanced non-small cell lung cancer (NSCLC) (1997) (0)
O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib (2005) (0)
Factors associated with survival in non-small cell lung cancer (NSCLC) patients with a solitary metastasis. (2013) (0)
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer (2023) (0)
Abstract C070: REAL variance in genomic testing by sex, age, race, ethnicity, and language: PROFILE database 7/2011 - 1/2022 (2023) (0)
C6-07: Mutations in the LKB1 tumor suppressor are frequently found in tumors from Caucasian NSCLC patients (2007) (0)
Transfection of the C-MYC proto-oncogene into classic small cell lung cancer (SCLC) cell lines causes phenotypic changes associated with C-MYC amplified variant SCLC lines (1985) (0)
Method for determining the response of cancer to treatments directed at the epidermal growth factor receptor (2005) (0)
P2.01-73 Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm (2018) (0)
Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy. (2012) (0)
Commentary (Johnson): Integration of Vinorelbine into Chemotherapy Strategies for Non-Small-Cell Lung Cancer (1995) (0)
Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast Cancer (MBC) (2023) (0)
Koyama et al-2016-Nat Commun - supplement (2016) (0)
P1-132: Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma (2007) (0)
535 Pilot and phase II study of low-dose rate BID chest radiotherapy (RT) for patients (PTS) with intrathoracic relapse of small cell lung cancer (SCLC) (1997) (0)
Clinical trial enrollment expansion to the community. (2016) (0)
Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors (2021) (0)
Abstract 370: Smoking history as an independent predictor for immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC) (2021) (0)
Abstract C100: Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1stline therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1) (2019) (0)
MA25.09 M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcom (2018) (0)
Safety of image guided research biopsies in patients with thoracic malignancies. (2022) (0)
B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC) (2020) (0)
Abstract PL04-01: Improving patient outcomes in lung cancer by targeting different driver mutations (2011) (0)
OP-JNCI180236 431..434 (2019) (0)
Different Combination Chemotherapy Regimens Lines from Patients with Small Cell Lung Cancer Treated with Family DNA Amplification in 107 Tumors and Tumor Cell myc (2006) (0)
636 A prospective study of atrial natriuretic peptide (ANP) and arginine vasopressin (AVP) in patients (PTS) with lung cancer (1997) (0)
Chromosome 3P in small cell lung cancer (1988) (0)
C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab (2007) (0)
6613 POSTER Prognostic factors for radical treatment of stage III NSCLC (2007) (0)
C1-02: Randomized Phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as 1st-line treatment for advanced NSCLC (2007) (0)
179 In vitro drug sensitivity testing to select chemotherapy for patients with lung cancer (1997) (0)
Cloning and Characterization of TCTA , a Gene Located at the Site of a t ( l ; 3 ) Translocation 1 (2006) (0)
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
P-521 Unresectable pulmonary carcinoid tumors: Response to therapy (2003) (0)
Comprehensivegenomiccharacterization of squamous cell lung cancers (2012) (0)
GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION (2019) (0)
Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity ofEGFRwild type cancers to gefitinib and cetuximab (2008) (0)
2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine". (2018) (0)
MTP10-01: Impact of genomic changes on the treatment of lung cancer (2007) (0)
Meta- analysis of EGF r Kinase inhibitors: Not a lways Greater t han the Sum of i ts Parts (2013) (0)
O-009 Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines (2005) (0)
Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer (2010) (0)
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC (2022) (0)
CHARACTERISTICS OF COLORECTAL CARCINOMA CELL LINES paraffin embedded sections of xenografts (2006) (0)
Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib. (2010) (0)
Associations between biomarker testing and characteristics of patients with metastatic non–small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data. (2022) (0)
Pulmonary Perspective The Impact of Genomic Changes on Treatment of Lung Cancer (2013) (0)
PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients (2019) (0)
Abstract CT215: Efficacy and safety of adjuvant (adj) atezolizumab (atezo) from the Phase 2 LCMC3 study (2023) (0)
Medical management of pulmonary carcinoid tumors. (2013) (0)
Stage I bronchioloalveolar carcinoma: Results of surgical treatment (2000) (0)
P2.06-019 A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC): Topic: Phase II + NK (2017) (0)
The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer (2020) (0)
Malignant Pleural Mesothelioma Inhibition of Epidermal Growth Factor Receptor Signaling in Updated (2002) (0)
AMetabolic Study of Patientswith Lung Cancer and Hyponatremia ofMalignancy (2006) (0)
P1.01-35 Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome (2018) (0)
557 Characterization of the p16 status of the tumor cell lines in the NCl drug screen panel identifies small molecule inhibitors of CDK4 (1997) (0)
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker (2023) (0)
The development of a short term in vitro culture system for bronchial biopsy specimens in patients with previously treated or suspected lung carcinoma (2000) (0)
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. (2022) (0)
Volumetric tumor growth in advanced NSCLC patients (pts) with EGFR mutations during EGFR-TKI therapy: Developing criteria to define slow progression. (2013) (0)
Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer (2023) (0)
Abstract 2063: Deep natural language processing for automated ascertainment of cancer outcomes from clinician progress notes (2020) (0)
A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer 1 (2001) (0)
The impact of 15 years of precision medicine innovation on the treatment of lung cancer. (2018) (0)
Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. (2023) (0)
D2-06: The impact of EGFR and KRAS genotype in chemotherapy-naive patients with advanced non-small cell lung cancer treated with erlotinib (2007) (0)
Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint (2015) (0)
Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients. (2018) (0)
566 Co-amplification of a novel cyclophilin-like gene with MYCL1 in small cell lung cancer (SCLC) cell lines (1997) (0)
Mutants Is Associated with Asymmetric Dimerization Derived EGF Receptor − Cetuximab Response of Lung Cancer (2013) (0)
Abstract PD7-07: Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis (2023) (0)
986 Immunization with mutant p53-and K-ras-derived peptides in cancer patients: Immune responses and clinical outcome (2003) (0)
Cloning and Characterization of TCTA, a Gene Located at the Site of a t(l;3) Translocation1 (2006) (0)
Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC). (2023) (0)
Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. (2023) (0)
Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs. (2015) (0)
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
Susceptibility Gene in Small Cell Lung Cancer Altered Structure and Expression of the Human Retinoblastoma (2006) (0)
Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas (2010) (0)
Defining equitable genomic testing uptake in gastrointestinal oncology: Ensuring capture of demographic data. (2023) (0)
Genomic profiling of breast cancer brain metastases reveals targetable alterations. (2020) (0)
Smoking history, drug toxicity, and survival in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs (2008) (0)
Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment (2020) (0)
PSY1-2 Expanding the reach of precision medicine in lung cancer (2021) (0)
In vitro drug sensitivity testing of cell lines from extensive vs limited small cell lung cancer (SCLC) patients (1994) (0)
c-Met is functional in lung cancer cell lines, and can effect various biological functions including alterations of cell motility with activation cytoskeletal proteins (2000) (0)
Radiotherapy Following Extrapleural Pneumonectomy(EPP) for Mesothelioma: The Brigham and Women’s Hospital Experience (2005) (0)
Abstract CT343: Phase II study of low-dose rate thoracic radiotherapy for treatment of intrathoracic relapsed or progressive small cell lung cancer (2014) (0)
Abstract 3890: Sequencing of 888 pediatric solid tumors informs precision oncology trial design and data sharing initiatives in pediatric cancer (2022) (0)
Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
Expanding the Reach of Targeted Therapy in Lung Cancer. (2017) (0)
Inhibition of theMet Receptor inMesothelioma (2005) (0)
P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor (2017) (0)
Predictive Biomarkers and Personalized Medicine Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer (2013) (0)
RESPONSE: Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer (2001) (0)
Cancer Research and Clinical Oncology for the Next Decade (2012) (0)
Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (2021) (0)
Phase I trial of extrapleural pneumonectomy [EPP], and intracavitary intraoperative hyperthermic [IOHC] cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. [MPM] (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bruce Evan Johnson?

Bruce Evan Johnson is affiliated with the following schools:

University of Tsukuba
Massachusetts General Hospital

Bruce Evan Johnson's Academic­Influence.com Rankings

Bruce Evan Johnson's Degrees

Why Is Bruce Evan Johnson Influential?

Bruce Evan Johnson's Published Works

Published Works

What Schools Are Affiliated With Bruce Evan Johnson?

Bruce Evan Johnson's AcademicInfluence.com Rankings